SNX25 Antibody

What is SNX25 and what are its primary cellular functions?

Sorting Nexin 25 (SNX25) belongs to the SNX family of proteins that play critical roles in cargo sorting and signaling from compartments within the endocytic network. SNX25 specifically regulates traffic of membrane proteins, including TGF-β receptors, and has been shown to negatively regulate TGF-β signaling by enhancing receptor degradation . Recent studies have also identified SNX25 as an important regulator of inflammatory responses in macrophages through inhibition of the NF-κB signaling pathway . The protein has a calculated molecular weight of 98 kDa, though it is observed at 98-105 kDa and sometimes at 65 kDa in experimental settings . SNX25 is widely expressed in the central nervous system and may also be involved in circadian rhythm generation .

What are the optimal experimental conditions for detecting SNX25 in different applications?

For Western Blot applications, SNX25 antibodies should be used at dilutions ranging from 1:2000 to 1:16000, depending on the specific antibody and sample type . When performing immunoprecipitation, use 0.5-4.0 μg of antibody for 1.0-3.0 mg of total protein lysate . For immunofluorescence or immunocytochemistry applications, dilutions of 1:200 to 1:800 are typically recommended . Positive Western Blot detection has been confirmed in multiple cell lines including EL-4, Raji, Jurkat, and C6 cells, as well as in mouse and rat brain tissue and mouse thymus tissue . For immunofluorescence applications, HeLa cells have shown reliable detection of SNX25 . It is essential to titrate antibodies in each specific experimental system to obtain optimal results, as signal strength can be sample-dependent.

What cell lines and tissue samples are most suitable for SNX25 research?

Based on validated experimental data, the following samples have demonstrated positive SNX25 detection:

For functional studies, the RAW 264.7 macrophage cell line has been successfully used for SNX25 knockdown experiments to investigate its role in inflammatory processes .

What critical criteria should researchers consider when selecting an SNX25 antibody?

When selecting an SNX25 antibody, researchers should consider:

• Validated applications: Ensure the antibody has been tested and validated for your specific application (WB, IP, IF/ICC) .

• Species reactivity: Verify the antibody recognizes SNX25 in your species of interest. Available antibodies have confirmed reactivity with human, mouse, and rat SNX25 .

• Clonality: Consider whether a polyclonal antibody (broader epitope recognition) or monoclonal antibody (higher specificity) is more suitable for your research question .

• Immunogen information: Review the immunogen used to generate the antibody. For example, some antibodies are raised against SNX25 fusion proteins while others use specific peptide sequences .

• Published literature: Check for publications that have successfully used the antibody in applications similar to yours.

• Recognition of specific isoforms: Note that SNX25 is observed at different molecular weights (98-105 kDa and 65 kDa) , so confirm the antibody detects the isoform relevant to your research.

How should researchers validate SNX25 antibodies before experimental use?

Proper validation of SNX25 antibodies should include:

• Positive and negative controls: Use tissues/cells known to express or lack SNX25. Based on available data, mouse brain tissue serves as an excellent positive control, while researchers can employ SNX25 knockdown samples as negative controls .

• Knockdown verification: Compare antibody signal in normal versus SNX25 siRNA-treated samples. Previous studies successfully used siRNA approaches to reduce SNX25 expression for validation purposes .

• Multiple detection methods: Confirm SNX25 detection using complementary techniques (e.g., both Western blot and immunofluorescence).

• Molecular weight verification: Confirm detection at the expected molecular weights (98-105 kDa and sometimes 65 kDa) .

• Blocking peptide competition: If available, use the immunizing peptide to compete with antibody binding to confirm specificity.

• Cross-reactivity assessment: Test for potential cross-reactivity with other sorting nexin family members, especially those with high sequence homology.

What storage and handling conditions ensure optimal SNX25 antibody performance?

SNX25 antibodies should be stored at -20°C and are typically stable for one year after shipment . The antibodies are generally supplied in a storage buffer containing PBS with 0.02% sodium azide and 50% glycerol at pH 7.3 . For most commercially available SNX25 antibodies, aliquoting is unnecessary for -20°C storage, reducing the risk of contamination and freeze-thaw cycles . Some preparations may contain 0.1% BSA as a stabilizer . Always avoid repeated freeze-thaw cycles, which can lead to degradation of the antibody and reduced performance . When working with the antibody, maintain cold chain practices and handle the reagent according to proper laboratory safety protocols, particularly noting the presence of sodium azide in the storage buffer.

How should researchers optimize Western blot protocols for SNX25 detection?

For optimal Western blot detection of SNX25:

• Sample preparation: Use RIPA or NP-40 lysis buffers with protease inhibitors. Tissue samples often require mechanical homogenization followed by detergent lysis.

• Protein loading: Load 20-40 μg of total protein per lane, adjusting based on expression levels in your sample.

• Gel selection: Use 8-10% polyacrylamide gels since SNX25 has a molecular weight of 98-105 kDa .

• Transfer conditions: Employ standard wet transfer methods with methanol-containing transfer buffer and PVDF membranes for optimal results.

• Blocking: Block membranes with 5% non-fat dry milk or BSA in TBST for 1 hour at room temperature.

• Primary antibody: Apply SNX25 antibody at dilutions between 1:2000 and 1:16000 in blocking buffer . Incubate overnight at 4°C for best results.

• Expected bands: Anticipate detecting bands at 98-105 kDa (major band) and possibly at 65 kDa (potential isoform or degradation product) .

• Controls: Include a positive control (e.g., mouse brain tissue lysate) and, if possible, SNX25 knockdown samples as a negative control .

• Stripping and reprobing: If performing multiple protein detections on the same membrane, use gentle stripping methods to preserve SNX25 epitopes.

What experimental approaches are effective for studying SNX25's role in immune regulation?

Based on published research, several approaches have proven effective for investigating SNX25's immunoregulatory functions:

• RNA interference: Use siRNA targeting SNX25 in macrophage cell lines (e.g., RAW 264.7) to study the effects of SNX25 knockdown on inflammatory responses. Two different siRNAs with varying efficiencies have been documented, with SNX25 siRNA-2 showing better knockdown efficiency (reducing SNX25 mRNA to 0.49 ± 0.0075-fold of control) .

• LPS stimulation: Treat SNX25 knockdown or overexpressing cells with lipopolysaccharide (LPS) to analyze the role of SNX25 in TLR4-mediated inflammatory responses. Studies have examined proinflammatory cytokine expression at 8 hours (mRNA) and 12 hours (protein) after LPS treatment .

• Cytokine expression analysis: Measure mRNA and protein levels of proinflammatory cytokines (IL-1β, TNF-α, IL-6) using RT-qPCR and Western blotting after modulating SNX25 expression .

• Signaling pathway analysis: Investigate MAPK (ERK, p38, JNK) and NF-κB signaling components to delineate the molecular mechanisms of SNX25 function. Previously, phosphorylation status at specific time points (e.g., 10, 20, and 30 minutes post-LPS) has revealed important insights into SNX25's regulatory mechanisms .

• Nuclear translocation assays: Separate nuclear and cytoplasmic fractions to examine p65 translocation to assess NF-κB pathway activation as affected by SNX25 .

• Ubiquitination analysis: Use proteasome inhibitors (e.g., MG132) to block protein degradation, then perform immunoprecipitation to detect ubiquitinated forms of IκBα as regulated by SNX25 .

How can researchers effectively perform SNX25 knockdown for functional studies?

For effective SNX25 knockdown experiments:

• siRNA selection: Two different siRNAs targeting SNX25 have been documented with varying efficiencies. SNX25 siRNA-2 demonstrated superior knockdown efficiency, reducing SNX25 mRNA levels to 0.49 ± 0.0075-fold of control, while SNX25 siRNA-1 achieved only 0.77 ± 0.10-fold reduction .

• Transfection optimization: For RAW 264.7 macrophages and similar cell lines, lipid-based transfection reagents have proven effective, but optimization of transfection conditions is essential for each cell type.

• Knockdown verification: Always confirm SNX25 knockdown at both mRNA level (by RT-qPCR) and protein level (by Western blotting) before proceeding with functional experiments .

• Timing considerations: Plan experiments with appropriate time points for both knockdown verification and subsequent functional assays. For instance, when studying LPS responses, SNX25 knockdown should be confirmed before LPS stimulation .

• Controls: Include a non-targeting (scrambled) siRNA control to account for non-specific effects of the transfection process .

• Rescue experiments: To confirm specificity, consider performing rescue experiments by re-expressing an siRNA-resistant SNX25 construct to restore normal phenotype.

• Alternative approaches: For longer-term studies, consider shRNA or CRISPR-Cas9 approaches for stable SNX25 knockdown or knockout.

How does SNX25 regulate the NF-κB signaling pathway in inflammatory responses?

Research indicates that SNX25 regulates the NF-κB signaling pathway through several mechanisms:

• IκBα degradation: SNX25 inhibits ubiquitin-mediated degradation of IκBα, the critical inhibitor of NF-κB. SNX25 knockdown promotes IκBα degradation after LPS stimulation (reducing levels to 0.72 ± 0.16-fold of control, p = 0.009), thereby enhancing NF-κB activation .

• Nuclear translocation of p65: SNX25 knockdown increases translocation of the p65 subunit of NF-κB from the cytoplasm to the nucleus. Studies have shown that SNX25 siRNA treatment decreases cytoplasmic p65 levels (0.74 ± 0.19-fold of control, p = 0.012) and increases nuclear p65 (1.50 ± 0.84-fold of control, p = 0.15) .

• IκBα ubiquitination: SNX25 appears to suppress ubiquitination of IκBα. When cells are treated with the proteasome inhibitor MG132, SNX25 knockdown cells show increased levels of poly-ubiquitinated IκBα compared to control cells after LPS stimulation .

• Paradoxical effects on signaling components: Interestingly, SNX25 knockdown decreases phosphorylation of IκBα (0.76 ± 0.14-fold of control, p = 0.046) and IKKβ (0.76 ± 0.050-fold of control, p = 0.00080) while still promoting IκBα degradation, suggesting that SNX25 may regulate NF-κB signaling through mechanisms beyond the canonical IKK-dependent pathway .

• JNK pathway interaction: SNX25 knockdown decreases JNK phosphorylation (0.65 ± 0.21-fold of control, p = 0.032) while increasing proinflammatory cytokine expression, suggesting complex cross-talk between different signaling pathways in which SNX25 participates .

Understanding these molecular mechanisms is crucial for developing targeted approaches to modulate inflammatory responses in various disease contexts.

What research questions about SNX25 remain underexplored and warrant further investigation?

Several important aspects of SNX25 biology remain underexplored:

• Structural determinants of function: How do specific domains within SNX25 contribute to its roles in endosomal trafficking versus inflammatory signaling? Structure-function studies using domain deletion or mutation approaches could address this question.

• Cell type-specific roles: While SNX25's function has been studied in macrophages , its roles in other immune cells and non-immune tissues, particularly in the central nervous system where it is highly expressed , remain to be elucidated.

• Physiological relevance: Development of tissue-specific or inducible knockout mouse models would help determine the physiological importance of SNX25 in inflammatory diseases, neurological disorders, and other pathological conditions.

• Regulatory mechanisms: How is SNX25 expression itself regulated during inflammation or in response to other stimuli? Transcriptional, post-transcriptional, and post-translational regulation of SNX25 remains largely unknown.

• Protein interactions: Comprehensive identification of SNX25 interaction partners beyond TGF-β receptors would provide insights into its diverse cellular functions.

• Therapeutic potential: Whether modulation of SNX25 activity could serve as a therapeutic approach for inflammatory disorders or other diseases has not been extensively explored.

• Relationship to other SNX family members: Potential functional redundancy or cooperation between SNX25 and other sorting nexins warrants investigation, particularly in tissues where multiple SNX proteins are expressed.

How can researchers interpret conflicting results in SNX25 signaling studies?

When confronting contradictory findings in SNX25 research:

What are common issues in SNX25 antibody experiments and how can they be resolved?

Common challenges in SNX25 antibody applications include:

• Multiple bands in Western blots: SNX25 is observed at both 98-105 kDa and 65 kDa . To distinguish specific signal from non-specific bands:

  • Use positive controls (e.g., mouse brain tissue) and SNX25 knockdown samples

  • Optimize primary antibody concentration (1:2000-1:16000 for Western blots)

  • Increase washing stringency to reduce background

• Weak signal in immunofluorescence: To improve SNX25 detection in IF/ICC:

  • Optimize fixation methods (consider comparing paraformaldehyde vs. methanol)

  • Test different antigen retrieval methods if applicable

  • Use signal amplification systems when necessary

  • Optimize antibody concentration (1:200-1:800 is recommended)

  • Increase antibody incubation time (overnight at 4°C often yields better results)

• Variability between experiments: For more consistent results:

  • Standardize sample preparation procedures

  • Prepare larger batches of buffers to use across experiments

  • Use consistent lots of antibodies when possible

  • Include internal controls in each experiment

  • Titrate the antibody in each testing system to obtain optimal results

• Immunoprecipitation efficiency: For successful SNX25 IP:

  • Use 0.5-4.0 μg antibody per 1.0-3.0 mg of total protein lysate

  • Pre-clear lysates to reduce non-specific binding

  • Optimize wash conditions to balance specificity with yield

  • Consider crosslinking the antibody to beads for cleaner results

What essential controls should be included in SNX25 research experiments?

For rigorous SNX25 research, include these essential controls:

• Positive tissue/cell controls: Mouse brain tissue, rat brain tissue, and cell lines including Raji, EL-4, and Jurkat cells have been validated for SNX25 expression .

• Knockdown/knockout controls: SNX25 siRNA-treated samples serve as negative controls and specificity validation. Published research used two different siRNAs with SNX25 siRNA-2 showing superior knockdown efficiency .

• Loading controls: For Western blots, use appropriate loading controls based on subcellular fraction being analyzed:

  • Total cell lysate: β-actin, GAPDH, or total protein staining

  • Nuclear fraction: Lamin B1 or Histone H3

  • Cytoplasmic fraction: GAPDH or α-tubulin

• Time course controls: When studying signaling events, include appropriate time points:

  • MAPK phosphorylation peaks at 20 minutes post-LPS stimulation

  • p65 phosphorylation peaks at 10 minutes post-LPS stimulation

  • Nuclear translocation of p65 peaks at 30 minutes post-LPS stimulation

  • IκBα degradation peaks at 20 minutes post-LPS stimulation

• Antibody controls: Include no-primary antibody controls in immunofluorescence to assess secondary antibody specificity and autofluorescence.

• Isotype controls: Particularly for co-immunoprecipitation experiments, include an isotype-matched non-specific antibody control.

• Ubiquitination controls: When studying ubiquitination of IκBα, include proteasome inhibitor (MG132) treated and untreated samples .

Including these controls ensures experimental rigor and facilitates accurate interpretation of results in SNX25 research.